Nobuhiro Ido

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients

Masayuki Masuda, Moe Matsumoto, Sachiko Tanaka et al. · Journal of Neuroimmunology · 2010 · 111 citations

Life Sciences, Endocrinology, Immunology +17

Nephrotic syndrome caused by protein thrombi in glomerulocapillary lumen in Waldenström's macroglobulinaemia

Yoshimi Harada, Nobuhiro Ido, Tomoya Okada et al. · British Journal of Haematology · 2000 · 16 citations

Medicine, Nephrology, Pathology +15

Clinical implications of the type 1/type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients

Masayuki Masuda, Sachiko Tanaka, Kanako Nakajima et al. · European Journal of Pharmacology · 2009 · 14 citations

Life Sciences, Endocrinology, Immunology +11

P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: Clinical implications and influence of glucocorticoid administration

Sachiko Tanaka, Masayuki Masuda, Kanako Nakajima et al. · International Immunopharmacology · 2008 · 11 citations

Life Sciences, Endocrinology, Immunology +11